Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodiesWilton B. Williams, Barton F. Haynes, Hua-Xin Liao et al.|Science|2015Cited by 202
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H. Mayer, Kelly E. Seaton, Yunda Huang et al.|PLoS Medicine|2017Cited by 132
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S. Li, Daniel E. Geraghty, Fusheng Li et al.|Journal of Clinical Investigation|2014Cited by 109
Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120Nina D. Russell, Lawrence Corey, Barney S. Graham et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006Cited by 104
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul Goepfert, Thomas G. Evans, Georgia D. Tomaras et al.|Vaccine|2006Cited by 93